Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hyaluronic Acid,Lidocaine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Revance Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement Revance will gain immediate and exclusive rights to commercialize TEOXANE’s RHA® line of fillers in the U.S.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 01, 2020
Lead Product(s) : Hyaluronic Acid,Lidocaine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Revance Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement